Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata.

ABSTRACT:

Background

The mechanisms driving alopecia areata (AA) are still unclear, hindering development of targeted therapeutics. Specific Th2 targeting with dupilumab in AA provides a unique opportunity to dissect its pathogenesis and explore the role of Th2 pathway.

Methods

We evaluated changes in scalp biomarkers in AA patients (with and without concomitant atopy) randomized to weekly dupilumab or placebo for 24 weeks, followed by open-label dupilumab for 24 weeks. Changes in biomarker levels were measured at weeks 12, 24, and 48 and were also correlated with clinical hair regrowth.

Results

At week 24, preceding clinical hair regrowth outcomes, only dupilumab-treated patients presented significant suppression of cellular infiltrates, and multiple Th2-related, markers (CCL1

SUBMITTER: Renert-Yuval Y 

PROVIDER: S-EPMC11344221 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature